There hadn’t been a major diagnostic advance for preeclampsia – a potentially life-threatening high blood pressure condition that develops in 5 to 7% of all pregnancies and disproportionately affects Black women – in over a century. But in May, the FDA cleared two tests developed by Thermo Fisher Scientific that, based on the concentration of certain biomarkers in the patient’s blood, can quickly predict whether a pregnant person hospitalized with hypertension will develop severe preeclampsia within the next two weeks. “It’s changing the way that clinicians are able to get an objective reading and then make a decision” to prioritize treatment or discharge the patient, says Tina Liedtky, president of Thermo Fisher Scientific’s clinical diagnostics division.
- Breaking Down the 2024 Election Calendar
- How Ukraine Beat Russia in the Battle of the Black Sea
- The Reintroduction of Kamala Harris
- Long COVID Looks Different in Kids
- What a $129 Frying Pan Says About America’s Eating Habits
- The 1 Heart-Health Habit You Should Start When You’re Young
- Cuddling Might Help You Get Better Sleep
- The 50 Best Romance Novels to Read Right Now